Nutanix, Inc. (NASDAQ:NTNX) is included in our list of the 12 oversold global stocks to invest in.
On November 26, 2025, Nutanix, Inc. (NASDAQ:NTNX) saw Morgan Stanley’s Sanjit Singh reiterate a “Buy” rating and reduce the price target to $82. The company reported 13% YoY revenue growth in Q1 to $670.6 million. Singh noted that this growth, though slightly below expectations due to several deals with deferred start dates, does not reflect deteriorating demand. Meanwhile, the company’s continued operational strength was highlighted by the analyst, including 18% ARR growth, 17% net-new ARR expansion, maintained FY26 operating margin guidance, and a $10 million boost to free cash flow guidance. These positives drove the analyst’s bullish stance.
Meanwhile, Nutanix, Inc. (NASDAQ:NTNX) reported fiscal Q1 2026 results on November 25, which marked resilient demand for its hybrid multicloud platform. This was evident from the quarter’s bookings, which came in slightly ahead of expectations. Furthermore, free cash flow remained strong at $174.5 million, up from $151.9 million in Q1 2025. While management noted some revenue shifting from Q1 to future quarters, they emphasized that total revenue over time remains the same.
Looking ahead, Nutanix, Inc. (NASDAQ:NTNX)’s management remains optimistic, thanks to continued partner momentum driven by expanded collaborations with Dell and Microsoft. Building on this perceived momentum, the company raised its free cash flow outlook for the year. Non-GAAP net income per share (diluted) of $0.41 was recorded for the quarter, which represents a YoY increase of $0.05.
Nutanix, Inc. (NASDAQ:NTNX) is focused on delivering a unified hybrid multicloud software platform that enables over 29,000 customers worldwide to run applications and manage data seamlessly.
While we acknowledge the potential of NTNX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best Small-Cap Biotech Stocks to Buy According to Analysts and 11 Overlooked Tech Stocks to Invest In.
Disclosure: None.